Medicines for which the Paul-Ehrlich-Institut is responsible, but which are not assigned to a particular group of medicines.
Search results 26 to 31 from a total of 31
| Name | Description | Marketing Authorisation Holder | Kind of Vaccine | License Number | License Date | Further Information |
|---|---|---|---|---|---|---|
|
Booster-StroVac |
Inaktivierte Keime spezifizierter Enterobakterien |
Strathmann GmbH & Co. KG |
weitere | PEI.H.03326.01.1 | 31.05.2006 | |
|
Booster-Gynatren |
Inaktivierte Keime spezifizierter Lactobacillus-Stämme |
Strathmann GmbH & Co. KG |
weitere | PEI.H.03325.01.1 | 31.05.2006 | |
BCGepha 100 mg |
Immunstimmulanzien |
APOGEPHA Arzneimittel GmbH |
weitere | PEI.H.12169.01.1 | 22.05.2023 | |
|
BCG-medac |
BCG zur Immunstimulation Therapie des oberflächlichen Harnblasentumors |
medac Gesellschaft für klinische Spezialpräparate mbH |
weitere | 151a/92 | 06.05.1993 | |
|
BCG medac |
Immunstimulans Therapie des oberflächlichen Harnblasentumors |
CC-Pharma GmbH |
weitere | PEI.H.03580.01.1 | 28.07.2010 | |
BCG Apogepha 100 mg |
Immunstimulans Therapie des oberflächlichen Harnblasentumors |
APOGEPHA Arzneimittel GmbH |
weitere | PEI.H.12057.01.1 | 01.08.2022 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 530 in BAnz AT 16.06.2025 B4.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 17.06.2025
